The World Health Organisation estimates that 450 million people worldwide experience mental health problems, preventing many from living long and healthy lives.

Bimuno, a second generation prebiotic developed by Clasado was used in a preclinical study on rats by the Department of Psychiatry, University of Oxford. During the study rats were fed fructooligosaccharide (FOS) or Bimuno. The results demonstrated that the modulation of gut microflora by Bimuno can positively affect changes in brain biochemistry. Brain Derived Neurotropic Factor (BDNF) molecule involved in the development and maintenance of neural cells increased with the ingestion of Bimuno.

The rats also showed an increase in a receptor critical for brain development, learning and memory. In contrast to many existing drug therapies used to treat mental health problems, Bimuno is free from unwanted side effects.

It is hoped that this latest research with second generation prebiotics may pave the way for further exciting discoveries and could lend to improvements in the quality of life for existing sufferers of mental health problems.

Bimuno has previously been linked to the prevention of Metabolic Syndrome and Clasado continue to subject their products to clinical trials, providing evidence linking the gut to various aspects of health.

Follow this link to read the published study in full.